237 related articles for article (PubMed ID: 21852812)
41. Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy.
Green KL; Southgate TD; Mulryan K; Fairbairn LJ; Stern PL; Gaston K
Hum Gene Ther; 2006 Feb; 17(2):147-57. PubMed ID: 16454648
[TBL] [Abstract][Full Text] [Related]
42. HPV 16 E2 protein induces apoptosis in human and murine HPV 16 transformed epithelial cells and has antitumoral effects in vivo.
Bermúdez-Morales VH; Peralta-Zaragoza O; Guzmán-Olea E; García-Carrancá A; Bahena-Román M; Alcocer-González JM; Madrid-Marina V
Tumour Biol; 2009; 30(2):61-72. PubMed ID: 19390235
[TBL] [Abstract][Full Text] [Related]
43. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
[TBL] [Abstract][Full Text] [Related]
44. Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes.
Steinwaerder DS; Carlson CA; Lieber A
Mol Ther; 2001 Sep; 4(3):211-6. PubMed ID: 11545611
[TBL] [Abstract][Full Text] [Related]
45. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
[TBL] [Abstract][Full Text] [Related]
46. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice.
Hoffmann C; Stanke J; Kaufmann AM; Loddenkemper C; Schneider A; Cichon G
J Immunother; 2010; 33(2):136-45. PubMed ID: 20145549
[TBL] [Abstract][Full Text] [Related]
47. [Detection of physical status of human papillomavirus 16 in cervical cancer tissue and SiHa cell line by multiplex real-time polymerase chain reaction].
Zheng Y; Peng ZL; Lou JY; Wang H
Ai Zheng; 2006 Mar; 25(3):373-7. PubMed ID: 16536998
[TBL] [Abstract][Full Text] [Related]
48. Adenoviral p53 effects and cell-specific E7 protein-protein interactions of human cervical cancer cells.
Choi JW; Ahn WS; Bae SM; Lee DB; Kim YW
Biosens Bioelectron; 2005 May; 20(11):2236-43. PubMed ID: 15797321
[TBL] [Abstract][Full Text] [Related]
49. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
[TBL] [Abstract][Full Text] [Related]
50. [Antisense targeting to human papillomavirus 18 E6/E7 affects the proliferation and apoptosis of human cervical carcinoma: an in vitro experiment with HeLa cells].
Sima N; Kong DB; Wang W; Lu YP; Wang SX; Ma D
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1618-21. PubMed ID: 17803852
[TBL] [Abstract][Full Text] [Related]
51. [RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer].
Peralta-Zaragoza O; Bermúdez-Morales VH; Madrid-Marina V
Rev Invest Clin; 2010; 62(1):63-80. PubMed ID: 20415061
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
53. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
Ma S; Qu W; Mao L; Zhu Z; Jia L; Zhao L; Zheng X
Oncol Rep; 2012 May; 27(5):1443-50. PubMed ID: 22294034
[TBL] [Abstract][Full Text] [Related]
54. HPV-16 E2 physical status and molecular evolution in vivo in cervical carcinomas.
Kahla S; Kochbati L; Chanoufi MB; Maalej M; Oueslati R
Int J Biol Markers; 2014 Mar; 29(1):e78-85. PubMed ID: 24170557
[TBL] [Abstract][Full Text] [Related]
55. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
[TBL] [Abstract][Full Text] [Related]
56. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
57. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.
Holland D; Hoppe-Seyler K; Schuller B; Lohrey C; Maroldt J; Dürst M; Hoppe-Seyler F
Cancer Res; 2008 Dec; 68(23):9964-72. PubMed ID: 19047178
[TBL] [Abstract][Full Text] [Related]
58. Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis.
Sanchez-Perez AM; Soriano S; Clarke AR; Gaston K
J Gen Virol; 1997 Nov; 78 ( Pt 11)():3009-18. PubMed ID: 9367388
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic potential of an adenovirus expressing p73 beta, a p53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo.
Das S; Somasundaram K
Cancer Biol Ther; 2006 Feb; 5(2):210-7. PubMed ID: 16481734
[TBL] [Abstract][Full Text] [Related]
60. Methylation status of HPV16 E2-binding sites classifies subtypes of HPV-associated oropharyngeal cancers.
Reuschenbach M; Huebbers CU; Prigge ES; Bermejo JL; Kalteis MS; Preuss SF; Seuthe IM; Kolligs J; Speel EJ; Olthof N; Kremer B; Wagner S; Klussmann JP; Vinokurova S; von Knebel Doeberitz M
Cancer; 2015 Jun; 121(12):1966-76. PubMed ID: 25731880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
